Lucius LuciVadadu Vadadustat 150mg

Product Information

• Product name: LuciVadadu Vadadustat 150mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Vadadustat
• Current strength: 150mg
• SKU: LU-ITEM-158
• Site category: other cancer

Product Summary

LuciVadadu Vadadustat 150mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Vadadustat is the active ingredient used for this product page. Public prescribing information for Vadadustat was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Vadadustat is a reversible inhibitor of HIF-prolyl-4-hydroxylases (PH)1, PH2, and PH3 (IC 50 in the nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, and increased production of erythropoietin (EPO).

Reference Indications

Vadadustat is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use Vadadustat has not been shown to improve quality of life, fatigue, or patient well-being. Vadadustat is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia In patients with anemia due to CKD not on dialysis . Vadadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use Not been shown to improve quality of life, fatigue, or patient well-being.

Reference Dosage and Administration

The public label should be checked for the indication-specific recommended dosage. Available administration instructions note that the medicine may be taken with or without food.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS Vadadustat increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) . Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels . No trial has identified a hemoglobin target level, dose of Vadadustat, or dosing strategy that does not increase these risks . Use the lowest dose of Vadadustat sufficient to reduce the need for red blood cell transfusions . WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS.

Common Adverse Reactions and Monitoring

The safety of Vadadustat was evaluated in adults with dialysis-dependent chronic kidney disease (DD-CKD) with anemia in the INNO 2 VATE-1 and INNO 2 VATE-2 trials . Both trials randomized patients to Vadadustat or darbepoetin alfa. Results in this section are based on the pooled Vadadustat treatment arms and pooled darbepoetin alfa arms from these trials. There were 1947 patients treated with Vadadustat and 1955 patients treated with darbepoetin alfa. Vadadustat was non-inferior to darbepoetin alfa on the time to first occurrence of major adverse cardiovascular events (MACE) in adults with anemia due to CKD who were on dialysis .

Drug Interactions and Special Populations

Iron supplements and iron-containing phosphate binders: Administer Vadadustat at least 1 hour before products containing iron. Non-iron-containing phosphate binders: Administer Vadadustat at least 1 hour before or 2 hours after non-iron-containing phosphate binders. Table with Vadadustat that Affect Vadadustat Exposure Iron supplements and phosphate binders Clinical Effect Co-administration with oral iron supplements, products containing iron, or phosphate binders decreases the exposure of vadadustat , which may reduce the effectiveness of Vadadustat. Prevention or Management Stagger administration when Vadadustat is used with oral iron supplements, products containing iron, iron-containing phosphate binders, or non-iron-containing phosphate binders .

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: VAFSEO public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.